Comparative-Effectiveness Research — Implications of the Federal Coordinating Council’s Report
P.H. Conway and C. Clancy
http://content.nejm.org/cgi/content/full/NEJMp0905631?query=TOC

The purpose of the National Comparative Effectiveness Summit is to provide an overview of the current status of comparative effectiveness research in the United States, to draw lessons for the CER experience in other countries and to identify the practical implications of CER for various actors in the healthcare industry, including payors and health plans, hospital and health systems, physician organizations, clinicians and other healthcare professionals and pharmaceutical, biotechnology and medical device manufacturers.

The organizers of the summit explain the will feature the following sessions:

SPECIAL PRECONFERENCE SESSION:
Assuring that Comparative Effectiveness Research Extends to Treatment Delivery Methods, including Inpatient Hospitalist and Chronic Care Delivery Methods

AND SPECIAL SESSIONS ON:

• Methods and Data Infrastructure Needed for Comparative Effectiveness Research
• The Advantages of Comparative Effectiveness Research
• The Limits of Comparative Effectiveness Research
• An Overview of Federal Stimulus Funding of Comparative Effectiveness Research
• The Role of AHRQ, HHS and NIH in Comparative Effectiveness Research
• Seeking Effectiveness in Health Care Reform: What’s at Play in Washington?
• The International Experience in Comparative Effectiveness Research
• Comparing Effectively:The Role of Registries in Comparative Effectiveness Research
• How States are Already Using Comparative and Cost-effective Research to Make Policy Decisions
• Balancing Act: CER and Innovation in U.S. Health Care
• The Implications of CER to Pharmaceutical Manufacturers
• The Implications of CER to Medical Device Manufacturers
• The Implications of CER for Private Health Insurers: Will it Impact Coverage and Payment?
• Operational CER in a Medicare Health Plan to Develop Effective and Efficient Delivery Systems and Clinical Programs
• The Implications of CER for Health System Group Purchasing Organizations
• Motivations and Incentives for Clinicians to Develop and Use CER Best Practices
• Can Consumers Use Comparative Effectiveness Information Effectively?

• Teresa Lee | Advanced Medical Technology Association (AdvaMed)
• Sanjay V. Joag, MD, PhD | Advocate Medical Group
• Susan L. Hildebrandt | American Academy of Family Physicians
• David T. Tayloe, Jr, MD, FAAP | American Academy of Pediatrics
• William Lang, MPH | American Association of Colleges of Pharmacy
• Tami L. Wahl | American Association for Health Freedom
• Edwin Webb | American College of Clinical Pharmacy
• Samuel Lin, MD, PhD, MBA, MPA, MS | American Medical Group Association
• James H. Bray, PhD | American Psychological Association
• Nancy Smith | Health Advancement Collaborative of Central New York
• Harrison Spencer | Association of Schools of Public Health
• Peter DeNucci | Apollo Publishing, Inc.
• John Lewis | Association of Clinical Research Organizations
• Frank Kondrad | AstraZeneca Pharmaceuticals
• Merrill Goozner | Center for Science in the Public Interest
• Christina Bethell, PhD, MBA, MPH |The Child and Adolescent Health Measurement Initiative
• William Vaughan | Consumers Union
• Michael E. Stuart | Delfini Group
• Martyn W.C. Howgill | Institute for Health Technology Studies (InHealth)
• Elisa Cascade | iGuard.org
• Raymond J. Baxter, PhD | Kaiser Permanente
• Sandra C. Raymond | Lupus Foundation of America
• Jordan Green | National Alliance for Caregiving
• Basit Chaudhry, MD, PhD | The National Coalition for Health Integration
• Hazel Moran | The National Working Group on Evidence-based Health Care
• Mark Leahy | Medical Device Manufacturers Association

To see the full list please visit the AHRQ website at: http://www.ahrq.gov/about/nac/test040309.htm